Goodsurance

Drug prices & Part D

Federal Subsidy That Has Held Down Standalone Medicare Drug Plan Premiums for Two Years Is Ending After 2026

CMS is closing the Part D Premium Stabilization Demonstration after 2026, and a KFF analysis warns that people with standalone prescription drug plans in traditional Medicare could face larger premium increases in 2027 than they have seen in recent years.

By the Goodsurance editorial teamSeptember 13, 2026

For the past two years, a federal demonstration program quietly reduced what people with traditional Medicare pay for standalone prescription drug plans. That support ends after 2026.

CMS announced on July 28, 2026, that it will not extend the Part D Premium Stabilization Demonstration into 2027. The agency said plan sponsors have gained enough experience operating under the Inflation Reduction Act's redesigned Part D benefit. The program cost approximately 9.8 billion dollars across its two years, according to a KFF analysis citing MedPAC data. Over that period, it reduced average standalone prescription drug plan premiums by 26 dollars per month in 2025 and 16 dollars per month in 2026.

The federal subsidy that kept standalone Medicare drug plan premiums lower ends after 2026. Check your 2027 costs before open enrollment opens October 15.

Without those subsidies, people enrolled in standalone Part D plans could face larger premium increases for 2027 than in recent years, KFF warned. CMS set the 2027 base beneficiary premium, the reference figure plans use to calculate individual premiums, at 41.33 dollars per month. The Inflation Reduction Act limits that base figure to grow no more than 6 percent annually through 2029.

About 24.9 million people were enrolled in standalone prescription drug plans in 2026. These are primarily people in traditional Medicare who want drug coverage without joining a Medicare Advantage plan.

CMS plans to release the full 2027 plan landscape, including actual plan-level premiums, in the second half of September. Anyone enrolled in a standalone drug plan should review the 2027 Annual Notice of Change when it arrives and compare available options before the annual enrollment period opens October 15.

In plain words

Medicare has had a program for two years that helped lower the cost of drug plans. That program ends after 2026. Starting in 2027, people who have a separate drug plan may pay more each month. About 24.9 million people have these plans. They are mainly people in regular Medicare who want drug coverage. The starting number used to set each plan's premium will be 41.33 dollars for 2027. Each plan sets its own final price. The real prices for 2027 plans will be posted later in September. Check your plan notice when it arrives and compare plans before open enrollment starts October 15.

Source: KFF
Read at the source →

More news

Other stories on what is moving in Medicare.

Drug prices & Part D

Medicare Part D Drug Spending Is Projected to Nearly Double by 2035, With GLP-1 Prescriptions as the Primary Driver

A KFF analysis of the 2026 Medicare Trustees Report projects annual Part D spending will climb from 181 billion dollars in 2025 to 346 billion dollars in 2035, a pace driven largely by surging use of GLP-1 drugs for diabetes and weight loss. The data arrives six weeks before open enrollment opens.

September 11, 2026

Drug prices & Part D

Face-to-Face Drug Price Talks Between Medicare and Manufacturers Close Today on 15 High-Cost Drugs

September 11 is the statutory deadline for in-person and virtual negotiation meetings in Medicare's third drug price negotiation cycle. Written offers are next, with a final CMS offer due September 30 and manufacturer responses due by November 1.

September 11, 2026

Drug prices & Part D

Comment Period Closes September 18 on How Drug Companies Must Apply Medicare-Negotiated Prices at Clinics and Doctor's Offices Starting in 2028

A CMS draft guidance describes the step-by-step process manufacturers must follow to make sure negotiated Medicare prices actually reach patients receiving infused or injected medicines at a doctor's office or outpatient clinic. Public comments are due September 18, 2026.

September 3, 2026

Drug prices & Part D

Medicare's Third Drug Negotiation Cycle Enters Its Final Month Before CMS Must Send Written Offers on 15 Drugs

CMS must issue final written maximum fair price offers to all 15 drug manufacturers in the third negotiation cycle by September 30. Companies then have until October 31 to accept or reject, with any agreed prices published by November 30 and taking effect in January 2028.

September 2, 2026

Drug prices & Part D

With Open Enrollment Weeks Away, Medicare Rights Center Recaps What the Inflation Reduction Act Has Delivered for Part D in 2026

An August 27 analysis from the Medicare Rights Center outlines the drug law's current protections, including a first-ever Part D out-of-pocket cap and ten negotiated drug prices that took effect in January.

August 30, 2026

Drug prices & Part D

CMS Opens a New Database This Fall to Track Discounted Drugs Sold Through Medicare Part D

Starting October 1, 2026, safety-net health providers that buy drugs at a 340B discount can voluntarily report those Part D claims to CMS, filling a gap that has made it harder to enforce inflation rebate rules accurately.

August 29, 2026